ARCHIVES

President Signs Supplemental Funding For NIH And FDA.

This article is from The Cancer Letter archive.

Vol. 34 No. 27 | July 11, 2008

Download PDF Visit The Full Archive

Related Articles

Fewer Side Effects With IMRT Than Traditional Radiation

August 31, 2007

Cancer Panel To Examine Health Of Phase I Trials

May 17, 1996

OCEANS Study: Avastin Shows Tumor Shrinkage in 79 Percent

June 24, 2011

Grantees Not In Danger Of Losing Cost-Free Biological Materials, But Can’t Have Chemicals

September 9, 1977

Troubles of Two Landmark Cancer Drugs, Celebrex and Iressa, Likely to Shape cancer Prevention, FDA Policy. FDA Mulls Withdrawal of Iressa.

January 7, 2005

Clinical Trials: NCI Forms Panel To Help Implement Recommendations

December 12, 1997